You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Human Bispecific Epidermal Growth Factor Receptor (EGFR)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

Recruiting
  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 21, 2023

EGFR Mutation-Related Tumors Trial (NX-019)

Not yet recruiting
  • EGFR Mutation-Related Tumors
  • (no location specified)
Aug 22, 2022

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

Breast Cancer Trial in Sarasota, Nashville (AC699)

Recruiting
  • Breast Cancer
  • Sarasota, Florida
  • +1 more
Jan 3, 2023

Breast Cancer Invasive Trial (pyrotinib)

Not yet recruiting
  • Breast Cancer Invasive
  • (no location specified)
Jun 18, 2023

Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T

Not yet recruiting
  • Recurrent Glioblastoma
  • Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
  • (no location specified)
Apr 4, 2023

Non Small Cell Lung Cancer Trial in Durham (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • Durham, North Carolina
    Duke University Medical Center
May 23, 2022

NSCLC Trial (Amivantamab, Lazertinib, Doxycycline)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Nov 7, 2023

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ocala, Florida
    Ocala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • (no location specified)
Aug 10, 2023

Breast Cancer Trial in Beijing, Zhengzhou, Changsha (EG017)

Not yet recruiting
  • Breast Cancer
  • Beijing, Benjing, China
  • +2 more
Dec 30, 2022

Real-world Data of Afatinib Treatment in First-line Setting and

Active, not recruiting
  • Non-squamous, Non-Small Cell Lung Cancer
  • Tokyo, Japan
    Nippon Boehringer Ingelheim Co., Ltd.
Jan 9, 2023

NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 24, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

Recruiting
  • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
  • Topical Timolol
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 14, 2023

NSCLC Trial (Mobocertinib 160 mg)

Approved for marketing
  • Carcinoma, Non-Small-Cell Lung
  • Mobocertinib 160 mg
  • (no location specified)
Sep 28, 2022

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer Trial (Trastuzumab,

Recruiting
  • Brain Metastases
  • +2 more
  • Saint Louis, Missouri
  • +1 more
Nov 8, 2022

Breast Cancer Trial (Tucatinib, Doxil)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Feb 17, 2023

Central Nervous System Metastatic EGFR Mutation Positive NSCLC

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 6, 2023

    Observes Afatinib as First-line Treatment and Sequential Therapy

    Active, not recruiting
    • Non-squamous, Non-Small Cell Lung Cancer
    • Beijing, China
    • +9 more
    Jan 9, 2023

    Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

    Recruiting
    • Locally Advanced or Unresectable Metastatic Breast Cancer
    • Stage IV Breast Cancer
    • Sacituzumab Govitecan-hziy
    • +3 more
    • Marietta, Georgia
    • +1 more
    Apr 21, 2023